Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil in previously treated cholangiocarcinoma
NCT04076761Phase 2Terminated
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in cholangiocarcinoma (CCA), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Median Progression-Free Survival up to 1 year. Started Dec 2019; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04076761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076761.